Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.

Respiratory disease caused by RSV infection is recognized as a severe public health issue in infants, young children and elderly with no specific treatment option. Vaccination may be the most effective strategy to combat this highly infectious virus although no vaccine has been approved. The novel vaccine candidate MVA-BN-RSV encodes RSV surface proteins F and G (subtypes A, B) as well as internal proteins N and M2 in the MVA-BN viral vector backbone to provide broad protection against RSV. This was a first in human study to investigate safety, reactogenicity and immunogenicity of MVA-BN-RSV. Sixty-three participants were allocated to 3 groups: adult (18-49 years) low (1 × 10

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors Daniela Reichhardt, Darja Schmidt, Liddy M Chen, Günter Silbernagl, Sanja Vidojkovic, Thomas PH Meyer, Elke Jordan, Tatiana Adams, Heinz Weidenthaler, Daria Stroukova, and Sonja De Carli are employees and stakeholders of Bavarian Nordic GmbH; Nathaly Samy is a consultant of Bavarian Nordic and Paul Chaplin is the company CEO.